ArticleClinical and vaccine immunology : CVI2007
European multicenter evaluation of commercial enzyme immunoassays for detecting norovirus antigen in fecal samples.
Article in Clinical and vaccine immunology : CVI, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 104 citations in OpenAlex.
- Advances and Future Perspective on Detection Technology of Human Norovirus.Pathogens (Basel, Switzerland) · 2021Review
- Review
- Norovirus strains in patients with acute gastroenteritis in rural and low-income urban areas in northern Brazil.Archives of virology · 2021Article
- Diversity of enteric and non-enteric human adenovirus strains in Brazil, 2006-2011.Archives of virology · 2021Article
- Performance evaluation of Automated Fluorescent Immunoassay System ROTA and NORO for detection of rotavirus and norovirus: A comparative study of assay performance with RIDASCREENJournal of clinical laboratory analysis · 2021Article
- Epidemiological, Molecular, and Clinical Features of Norovirus Infections among Pediatric Patients in Qatar.Viruses · 2019Article
- Norovirus Infection in Older Adults: Epidemiology, Risk Factors, and Opportunities for Prevention and Control.Infectious disease clinics of North America · 2017Review
- Characterization of cross-reactive norovirus-specific monoclonal antibodies.Clinical and vaccine immunology : CVI · 2015Article
- Norovirus.Clinical microbiology reviews · 2015Review
- Identification of human single-chain antibodies with broad reactivity for noroviruses.Protein engineering, design & selection : PEDS · 2014Article
- Detection of circulating norovirus genotypes: hitting a moving target.Virology journal · 2014Article
- New strategies for evaluation and analysis of SELEX experiments.BioMed research international · 2014Article
- Epidemiology, prevention, and control of the number one foodborne illness: human norovirus.Infectious disease clinics of North America · 2013Review
- Pattern of activation of human antigen presenting cells by genotype GII.4 norovirus virus-like particles.Journal of translational medicine · 2013Article
- Evaluation of third-generation ELISA and a rapid immunochromatographic assay for the detection of norovirus infection in fecal samples from inpatients of a German tertiary care hospital.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2012Article
- Norovirus infections in children under 5 years of age hospitalized due to the acute viral gastroenteritis in northeastern Poland.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2012Article
- Evaluation of a new immunochromatographic assay kit for the rapid detection of norovirus in fecal specimens.Annals of laboratory medicine · 2012Article
- Scientific Opinion on an update on the present knowledge on the occurrence and control of foodborne viruses.EFSA journal. European Food Safety Authority · 2011Article
- Electronic outbreak surveillance in Germany: a first evaluation for nosocomial norovirus outbreaks.PloS one · 2011Article
- Diagnostic accuracy and analytical sensitivity of IDEIA Norovirus assay for routine screening of human norovirus.Journal of clinical microbiology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A total of 2,254 fecal samples were tested in a European multicenter evaluation of commercially available norovirus antigen detection assays. Two commercial enzyme immunoassays, IDEIA Norovirus (Oxoid; Thermo Fisher Scientific, Ely, United Kingdom) and RIDASCREEN Norovirus (R-Biopharm, Darmstadt, Germany), were included in the evaluation, and their performance was compared with the results of reverse transcription-PCR (RT-PCR). Included in the evaluation were samples collected in sporadic cases of gastroenteritis, samples from outbreaks in which two or more samples were collected, well-characterized samples representing genotypes currently cocirculating within Europe, and samples collected from patients with gastroenteritis caused by a pathogen other than norovirus. The sensitivities and specificities of the IDEIA Norovirus and RIDASCREEN Norovirus assays were 58.93 and 43.81% and 93.91 and 96.37%, respectively, compared with RT-PCR. The sensitivities of both assays for outbreak investigations improved when six or more samples from an outbreak were examined. The IDEIA Norovirus assay exhibited reactivity to a broader range of norovirus genotypes than the RIDASCREEN Norovirus assay, which showed genotype-dependent sensitivities. The results indicate that, if used, these assays should serve as screening assays and the results should be confirmed by RT-PCR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.